Free Trial
→ Elon's next millionaires start October 24? (From Behind the Markets) (Ad)tc pixel
NASDAQ:BIAF

bioAffinity Technologies Q4 2025 Earnings Results & Report

bioAffinity Technologies logo
$3.52 -0.12 (-3.17%)
As of 02:54 PM Eastern
This is a fair market value price provided by Massive. Learn more.

bioAffinity Technologies beat analyst expectations on both earnings and revenue in its Q4 2025 results, released March 14, 2026. The company reported EPS of -$16.65 versus the -$40.50 consensus estimate, while revenue of $1.59 million topped the $1.55 million estimate by $0.04 million.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q4 2025
Report Date
Time
Before Market Opens

bioAffinity Technologies EPS Results

Actual EPS
-$16.65
Consensus EPS
-$40.50
Beat/Miss
Beat by +$23.85
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 7 quarters

bioAffinity Technologies Revenue Results

Actual Revenue
$1.59 million
Expected Revenue
$1.55 million
Beat/Miss
Beat by +$39.81 thousand
YoY Revenue Growth
N/A

Upcoming Earnings

bioAffinity Technologies' Q3 2026 earnings is estimated for Wednesday, November 18, 2026, based on past reporting schedules

Conference Call Resources

Powered by Quartr

Earnings Documents

bioAffinity Technologies' Q4 2025 Press ReleasePress Release
(8-K)
bioAffinity Technologies' Q4 2025 Annual reportAnnual report
(10-K)

bioAffinity Technologies Q4 2025 Earnings FAQ

bioAffinity Technologies (NASDAQ:BIAF) reported earnings of -$16.65 per share for Q4 2025, beating the consensus estimate of -$40.50. The report was announced on Saturday, March 14, 2026.

bioAffinity Technologies reported revenue of $1.59 million for Q4 2025, against a consensus estimate of $1.55 million.

bioAffinity Technologies' next earnings date is estimated for Wednesday, November 18, 2026. MarketBeat tracks confirmed and estimated earnings dates for bioAffinity Technologies on the company's earnings history page.

bioAffinity Technologies Earnings Headlines

bioAffinity to Present New Sputum-Based Lung Biomarker Data
October 13 at 9:51 AM  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/bioaffinity-to-present-new-sputum-based-lung-biomarker-data?utm_source=marketbeat.com&utm_medium=referral
BioAffinity Technologies Closes $4 Million Direct Offering, Private Placement
October 9, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/bioaffinity-technologies-closes-4-million-161341113.html
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.tc pixel
October 14 at 1:00 AM  |  Profits Run (Ad)
bioAffinity Technologies Completes New $4 Million Financing
October 9, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/bioaffinity-technologies-completes-new-4-million-financing?utm_source=marketbeat.com&utm_medium=referral
WallachBeth Capital Announces Closing of bioAffinity Technologies $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
October 9, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/wallachbeth-capital-announces-closing-of-bioaffinity-technologies-4-million-registered-direct-financing-of-common-stock-and-concurrent-private-placement-priced-at-the-market-under-nasdaq-rules-302903691.html
bioAffinity Technologies, Inc. Announces Closing of $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
October 9, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20261009218447/en/bioaffinity-technologies-inc.-announces-closing-of-4-million-registered-direct-financing-of-common-stock-and-concurrent-private-placement-priced-at-the-market-under-nasdaq-rules/
See More bioAffinity Technologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like bioAffinity Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on bioAffinity Technologies and other key companies, straight to your email.

About bioAffinity Technologies

bioAffinity Technologies (NASDAQ:BIAF) is a biotechnology company focused on developing diagnostic and therapeutic products for cancer and other diseases. The company’s technology platform uses porphyrin-based compounds designed to selectively interact with cancer cells, supporting applications in disease detection and treatment.

Its lead diagnostic product, CyPath Lung, is a noninvasive urine-based test being developed to aid in the detection of lung cancer. The test is designed to use a porphyrin-based agent that interacts with abnormal cells in the lungs and can subsequently be detected in a urine sample. CyPath Lung has received Breakthrough Device designation from the U.S. Food and Drug Administration, although regulatory status and availability may vary by jurisdiction.

bioAffinity Technologies is headquartered in Albuquerque, New Mexico, and serves the medical and biotechnology markets through the development of products intended to improve the early identification and treatment of cancer. The company is led by Maria Zannes, who serves as president and chief executive officer.

View bioAffinity Technologies Profile
Earnings Tools